Tags : Lenvima

Regulatory

Merck’s Keytruda (pembrolizumab) + Eisai’s Lenvima (lenvatinib) Receives FDA’s Approval

Shots: The approval is based on P-II KEYNOTE-146/Study 111 assessing Keytruda (200mg, IV, q3w) + Lenvima (20mg, PO, qd) in 108 patients with metastatic endometrial carcinoma that is not microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) with diseases progression following prior systemic therapy and are not candidates for curative surgery or radiation The P-II KEYNOTE-146/Study 111 […]Read More

Pharma

Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA’s

Shots: The third BT designation is based on P-Ib KEYNOTE-524 study assessing Keytruda (200mg, IV, q3w) + Lenvima (12/8 mg/day) in patients with unresectable HCC not amenable to locoregional treatment The dual regimen has received its first two BT designation for advanced and metastatic renal carcinoma and non-microsatellite instability-high/proficient mismatch repair endometrial carcinoma in Jan’18 […]Read More